FindTrial
Sign In

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00508963
Enrollment
Unknown
Registered
2007-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous

Keywords

New World Cutaneous or Mucocutaneous Leishmaniasis

Brief summary

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Interventions

DRUGsodium stibogluconate (Pentostam)

20 mg/kg IV every day for 20 or 28 days

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Biopsy proven new world cutaneous or mucocutaneous leishmania

Exclusion criteria

* Prolonged QT * Liver disease * Pancreatitis

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026